Moderate to Severe Plaque Psoriasis

Immunology
16
Pipeline Programs
8
Companies
17
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
3
0
8
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
7100%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

UP
BIMZELXApproved
bimekizumab
UCB Pharma
injection2023

Competitive Landscape

8 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
5 programs
1
1
3
1
bimekizumabPhase 3Monoclonal Antibody1 trial
bimekizumabPhase 3Monoclonal Antibody1 trial
bimekizumabPhase 3Monoclonal Antibody1 trial
bimekizumabPhase 2Monoclonal Antibody1 trial
BimekizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06888193Recruiting20Est. May 2027
NCT04718896Completed41Est. Mar 2025
NCT06425549Recruiting168Est. Nov 2030
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
2
ABT-874Phase 3
ABT-874Phase 3
Documentation of Humira in Psoriasis Patients in Routine Clinical PracticeN/A
Abbott
AbbottABBOTT PARK, IL
3 programs
1
2
ABT-874Phase 31 trial
ABT-874Phase 33 trials
briakinumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01260844Withdrawn12
NCT00710580Completed350Est. Apr 2009
NCT00870948Completed75
+2 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
210 mg brodalumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01708603TerminatedEst. Oct 2015
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-488 TabletsPhase 21 trial
Active Trials
NCT06109818Completed129Est. Sep 2024
Nimbus Therapeutics
1 program
1
NDI-034858 study drugPhase 2
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
CT303Phase 11 trial
Active Trials
NCT05258331UnknownEst. Dec 2024
Novartis
NovartisBASEL, Switzerland
1 program
1
MidazolamPhase 14 trials
Active Trials
NCT07340190Not Yet Recruiting24Est. Dec 2029
NCT05236530Completed48Est. Oct 2022
NCT02607774Completed25Est. Dec 2016
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
UCB Pharmabimekizumab
UCB Pharmabimekizumab
UCB Pharmabimekizumab
Bausch Health210 mg brodalumab
AbbottABT-874
AbbottABT-874
AbbottABT-874
InnoCareICP-488 Tablets
UCB Pharmabimekizumab
NovartisMidazolam
UCB PharmaBimekizumab
NovartisMidazolam
GC BiopharmaCT303
NovartisMidazolam
NovartisMidazolam

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 3,680 patients across 17 trials

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Start: Jul 2024Est. completion: Mar 202890 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Start: Jun 2024Est. completion: Nov 2030168 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Start: Sep 2021Est. completion: Sep 202247 patients
Phase 3Completed
NCT01708603Bausch Health210 mg brodalumab

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Start: Aug 2012Est. completion: Oct 2015
Phase 3Terminated

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Start: Jul 2008Est. completion: Apr 2009350 patients
Phase 3Completed

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Start: Apr 2008Est. completion: Nov 2009317 patients
Phase 3Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Start: Feb 2008Est. completion: Oct 20112,301 patients
Phase 3Completed
NCT06109818InnoCareICP-488 Tablets

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Start: Jan 2024Est. completion: Sep 2024129 patients
Phase 2Completed

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Start: Apr 2021Est. completion: Mar 202541 patients
Phase 2Completed

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Start: May 2026Est. completion: Dec 202924 patients
Phase 1Not Yet Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Start: Nov 2025Est. completion: May 202720 patients
Phase 1Recruiting

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir

Start: Mar 2022Est. completion: Oct 202248 patients
Phase 1Completed

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Start: Oct 2021Est. completion: Dec 2024
Phase 1Unknown

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Start: Dec 2015Est. completion: Dec 201625 patients
Phase 1Completed

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Start: Oct 2015Est. completion: Dec 201733 patients
Phase 1Completed

Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Start: Apr 201112 patients
Phase 1Withdrawn

Phase 1 BA Study, Single Center With Healthy Volunteers

Start: Jan 200975 patients
Phase 1Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 3,680 patients
8 companies competing in this space